U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 2 Cutaneous Follicular Lymphoma

MedGen UID:
232246
•Concept ID:
C1333836
•
Neoplastic Process

Definition

A cutaneous lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 2 Cutaneous Follicular Lymphoma

Professional guidelines

PubMed

Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Cheson BD, Morschhauser F, Martin P
Clin Lymphoma Myeloma Leuk 2020 Sep;20(9):563-571. Epub 2020 Mar 20 doi: 10.1016/j.clml.2020.03.009. PMID: 32303486
Single centre study of using bendamustine in the treatment of B-cell malignancies.
Osmani AH, Masood N
J Pak Med Assoc 2013 Jun;63(6):702-6. PMID: 23901668

Recent clinical studies

Etiology

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA, Brown LE, Prakash S, Bhargava P
Pathology 2021 Apr;53(3):349-366. Epub 2021 Mar 5 doi: 10.1016/j.pathol.2021.01.002. PMID: 33685720
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators
J Clin Oncol 2019 May 10;37(14):1188-1199. Epub 2019 Mar 21 doi: 10.1200/JCO.19.00010. PMID: 30897038Free PMC Article
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators
N Engl J Med 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PMID: 30184451Free PMC Article
Primary cutaneous large B-cell lymphoma: the relation between morphology, clinical presentation, immunohistochemical markers, and survival.
Fernández-Vázquez A, Rodríguez-Peralto JL, Martínez MA, Platón EM, Algara P, Camacho FI, López-Ríos F, Zarco C, Sánchez-Yus E, Fresno MF, Barthe L, Aliaga A, Fraga M, Forteza J, Oliva H, Piris MA
Am J Surg Pathol 2001 Mar;25(3):307-15. doi: 10.1097/00000478-200103000-00004. PMID: 11224600

Diagnosis

CD30 expression in cutaneous B-cell lymphomas.
Afolayan-Oloye O, Zhao L, Tejasvi T, Chan MP, Harms PW, Fullen DR, Wilcox RA, Hristov AC
J Cutan Pathol 2023 Sep;50(9):819-827. Epub 2023 Jun 8 doi: 10.1111/cup.14473. PMID: 37290910
Concurrent Presentation of Mycosis Fungoides and Primary Cutaneous Marginal Zone LPD: Clinicopathological Study of 4 Cases and Literature Review.
Prieto-Torres L, Machan S, Haro R, Cerroni L, Requena L, Rodríguez-Pinilla SM
Am J Dermatopathol 2023 Mar 1;45(3):163-169. Epub 2023 Jan 10 doi: 10.1097/DAD.0000000000002378. PMID: 36728288
New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA, Brown LE, Prakash S, Bhargava P
Pathology 2021 Apr;53(3):349-366. Epub 2021 Mar 5 doi: 10.1016/j.pathol.2021.01.002. PMID: 33685720
Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.
Eelloo JA, Smith MJ, Bowers NL, Ealing J, Hulse P, Wylie JP, Shenjere P, Clarke NW, Soh C, Whitehouse RW, Jones M, Duff C, Freemont A, Gareth Evans D
Fam Cancer 2019 Oct;18(4):445-449. doi: 10.1007/s10689-019-00138-4. PMID: 31240424
Cutaneous immunoblastic T-cell lymphoma.
Schmoeckel C, Burg G, Hoffmann-Fezer G, Stolz W, Weitz H, Löhrs U, Braun-Falco O
Arch Dermatol Res 1982;274(1-2):141-54. doi: 10.1007/BF00510367. PMID: 6984639

Therapy

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators
J Clin Oncol 2019 May 10;37(14):1188-1199. Epub 2019 Mar 21 doi: 10.1200/JCO.19.00010. PMID: 30897038Free PMC Article
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators
N Engl J Med 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PMID: 30184451Free PMC Article
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W
Br J Dermatol 2005 Jul;153(1):167-73. doi: 10.1111/j.1365-2133.2005.06659.x. PMID: 16029344
DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
LeMaistre CF
Clin Lymphoma 2000 Nov;1 Suppl 1:S37-40. PMID: 11707862

Prognosis

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators
N Engl J Med 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PMID: 30184451Free PMC Article
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W
Br J Dermatol 2005 Jul;153(1):167-73. doi: 10.1111/j.1365-2133.2005.06659.x. PMID: 16029344
Primary cutaneous large B-cell lymphoma: the relation between morphology, clinical presentation, immunohistochemical markers, and survival.
Fernández-Vázquez A, Rodríguez-Peralto JL, Martínez MA, Platón EM, Algara P, Camacho FI, López-Ríos F, Zarco C, Sánchez-Yus E, Fresno MF, Barthe L, Aliaga A, Fraga M, Forteza J, Oliva H, Piris MA
Am J Surg Pathol 2001 Mar;25(3):307-15. doi: 10.1097/00000478-200103000-00004. PMID: 11224600
Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Brice P, Cazals D, Mounier N, Verola O, Neidhart-Berard AM, Remenieras L, Deconinck E, Doyen C, Hamelsand J, Molina T, Moulonguet I, Gisselbrecht C
Leukemia 1998 Feb;12(2):213-9. doi: 10.1038/sj.leu.2400911. PMID: 9519784

Clinical prediction guides

Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Cheson BD, Morschhauser F, Martin P
Clin Lymphoma Myeloma Leuk 2020 Sep;20(9):563-571. Epub 2020 Mar 20 doi: 10.1016/j.clml.2020.03.009. PMID: 32303486
Cutaneous B-cell pseudolymphoma at the site of vaccination.
Cerroni L, Borroni RG, Massone C, Chott A, Kerl H
Am J Dermatopathol 2007 Dec;29(6):538-42. doi: 10.1097/DAD.0b013e3181591bea. PMID: 18032948
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Weller E, Horning SJ
Leuk Lymphoma 2007 Dec;48(12):2397-402. Epub 2007 Oct 13 doi: 10.1080/10428190701694186. PMID: 17943599
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W
Br J Dermatol 2005 Jul;153(1):167-73. doi: 10.1111/j.1365-2133.2005.06659.x. PMID: 16029344
DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
LeMaistre CF
Clin Lymphoma 2000 Nov;1 Suppl 1:S37-40. PMID: 11707862

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...